These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 7680058)

  • 1. A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients.
    Kozal MJ; Shafer RW; Winters MA; Katzenstein DA; Merigan TC
    J Infect Dis; 1993 Mar; 167(3):526-32. PubMed ID: 7680058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients.
    Kozal MJ; Shafer RW; Winters MA; Katzenstein DA; Aguiniga E; Halpern J; Merigan TC
    J Acquir Immune Defic Syndr (1988); 1994 Aug; 7(8):832-8. PubMed ID: 7517448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy.
    Kozal MJ; Kroodsma K; Winters MA; Shafer RW; Efron B; Katzenstein DA; Merigan TC
    Ann Intern Med; 1994 Aug; 121(4):263-8. PubMed ID: 7518658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations.
    Shafer RW; Kozal MJ; Winters MA; Iversen AK; Katzenstein DA; Ragni MV; Meyer WA; Gupta P; Rasheed S; Coombs R
    J Infect Dis; 1994 Apr; 169(4):722-9. PubMed ID: 8133086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects.
    Boucher CA; O'Sullivan E; Mulder JW; Ramautarsing C; Kellam P; Darby G; Lange JM; Goudsmit J; Larder BA
    J Infect Dis; 1992 Jan; 165(1):105-10. PubMed ID: 1370174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team.
    Shafer RW; Iversen AK; Winters MA; Aguiniga E; Katzenstein DA; Merigan TC
    J Infect Dis; 1995 Jul; 172(1):70-8. PubMed ID: 7541064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The appearance of drug resistance-associated point mutations in HIV type 1 plasma RNA precedes their appearance in proviral DNA.
    Kaye S; Comber E; Tenant-Flowers M; Loveday C
    AIDS Res Hum Retroviruses; 1995 Oct; 11(10):1221-5. PubMed ID: 8573378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of human immunodeficiency virus RNA in plasma and cellular viral DNA genotypic zidovudine resistance and viral load during zidovudine-didanosine combination therapy.
    Holodniy M; Mole L; Margolis D; Moss J; Dong H; Boyer E; Urdea M; Kolberg J; Eastman S
    J Virol; 1995 Jun; 69(6):3510-6. PubMed ID: 7745698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zidovudine resistance mutations and human immunodeficiency virus type 1 DNA burden: longitudinal evaluation of six patients under treatment.
    Zazzi M; Catucci M; De Milito A; Romano L; Venturi G; Almi P; Gonnelli A; Rubino M; Valensin PE
    Infection; 1996; 24(6):419-25. PubMed ID: 9007588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of zidovudine resistance-associated genotypes in human immunodeficiency virus type 1-infected patients.
    Cleland A; Watson HG; Robertson P; Ludlam CA; Brown AJ
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 May; 12(1):6-18. PubMed ID: 8624762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency virus type 1 isolates.
    Boucher CA; van Leeuwen R; Kellam P; Schipper P; Tijnagel J; Lange JM; Larder BA
    Antimicrob Agents Chemother; 1993 Jul; 37(7):1525-30. PubMed ID: 8103317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine.
    de Jong MD; Veenstra J; Stilianakis NI; Schuurman R; Lange JM; de Boer RJ; Boucher CA
    Proc Natl Acad Sci U S A; 1996 May; 93(11):5501-6. PubMed ID: 8643604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of mutations associated with zidovudine resistance in human immunodeficiency virus by use of the polymerase chain reaction.
    Richman DD; Guatelli JC; Grimes J; Tsiatis A; Gingeras T
    J Infect Dis; 1991 Dec; 164(6):1075-81. PubMed ID: 1720152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of primary resistance to zidovudine and lamivudine in drug-naive human immunodeficiency virus type-1 infected patients: high proportion of reverse transcriptase codon 215 mutant in circulating lymphocytes and free virus.
    Trabaud MA; Leriche-Guerin K; Regis C; Bordes I; Cotte L; Detmer J; Kolberg J; Ritter J; Trépo C
    J Med Virol; 2000 Jul; 61(3):352-9. PubMed ID: 10861645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human immunodeficiency virus proviral DNA from peripheral blood and lymph nodes demonstrates concordant resistance mutations to zidovudine (codon 215) and didanosine (codon 74). Division of AIDS Treatment Research Initiative 003 Study Group.
    Mayers D; Bethel J; Wainberg MA; Weislow O; Schnittman S
    J Infect Dis; 1998 Jun; 177(6):1730-3. PubMed ID: 9607859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Provirus load changes in untreated and zidovudine-treated human immunodeficiency virus type 1-infected patients.
    Luque F; Caruz A; Pineda JA; Torres Y; Larder B; Leal M
    J Infect Dis; 1994 Feb; 169(2):267-73. PubMed ID: 7906288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of selective polymerase chain reaction primers and differential probe hybridization of polymerase chain reaction products for determination of relative amounts of codon 215 mutant and wild-type HIV-1 populations.
    Eastman PS; Urdea M; Besemer D; Stempien M; Kolberg J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jul; 9(3):264-73. PubMed ID: 7540490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zidovudine susceptibility testing of human immunodeficiency virus type 1 (HIV) clinical isolates.
    Shafer RW; Kozal MJ; Katzenstein DA; Lipil WH; Johnstone IF; Merigan TC
    J Virol Methods; 1993 Mar; 41(3):297-310. PubMed ID: 8097199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid CD4+ cell decline after sexual transmission of a zidovudine-resistant syncytium-inducing isolate of HIV-1.
    Kuritzkes DR; Bell S; Bakhtiari M
    AIDS; 1994 Jul; 8(7):1017-9. PubMed ID: 7524542
    [No Abstract]   [Full Text] [Related]  

  • 20. Peripheral blood mononuclear cell human immunodeficiency virus type 1 proviral DNA quantification by polymerase chain reaction: relationship to immunodeficiency and drug effect.
    Montoya JG; Wood R; Katzenstein D; Holodny M; Merigan TC
    J Clin Microbiol; 1993 Oct; 31(10):2692-6. PubMed ID: 7902845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.